Literature DB >> 30854932

Clinicopathological and molecular differences in colorectal cancer according to location.

Yu-Lun Hsu1,2, Chun-Chi Lin1,2, Jeng-Kai Jiang1,2, Hung-Hsin Lin1,2, Yuan-Tzu Lan1,2, Huann-Sheng Wang1,2, Shung-Haur Yang1,2, Wei-Shone Chen1,2, Tzu-Chen Lin1,2, Jen-Kou Lin1,2, Pei-Ching Lin3,4, Shih-Ching Chang1,2.   

Abstract

PURPOSE: The incidence, pathogenesis, molecular pathways, and outcomes of colorectal cancer vary depending on the location of the tumor. This study aimed to compare the difference in tumor characteristics and the outcome between right-sided colon cancer and left-sided colorectal cancer (LCRC).
MATERIALS AND METHODS: A total of 1503 patients with colorectal cancer who underwent surgery at the Taipei Veterans General Hospital between 2000 and 2010 were enrolled in this study. Right-sided colon cancer was defined as cancers in the cecum, ascending colon, and transverse colon, while LCRC was defined as cancers in the splenic flexure colon, descending colon, sigmoid colon, and rectum. The endpoint was overall survival. The mutations were detected via polymerase chain reaction and MASS array. The prognostic value was determined using the log-rank test and the Cox regression analysis.
RESULTS: A total of 407 and 1096 cases were classified as right-sided colon cancer and LCRC, respectively. Compared to patients with LCRC, those with right-sided colon cancer had more mucinous type cancer (7.4% vs. 3.5%), poorly differentiated tumor (11.5% vs. 3.6%), and advanced tumor-node-metastasis stage. The risk for peritoneal tumor seeding was higher in the right-sided colon cancer group (12.8% vs. 5.7%). Overall survival was better in LCRC than in right-sided colon cancer ( P=0.036).
CONCLUSIONS: In our study, right-sided colon cancer had a more advanced tumor stage, a higher risk of peritoneal metastasis, and a poorer outcome than LCRC. Moreover, right-sided colon cancer had more gene mutations in BRAF, KRAS, SMAD4, TGF-β, PIK3CA, PTEN, AKT1, and high microsatellite instability.

Entities:  

Keywords:  Clinicopathologic; colorectal cancer; location; molecule; overall survival

Mesh:

Year:  2019        PMID: 30854932     DOI: 10.1177/1724600818807164

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  6 in total

1.  Nomogram model characterized by mutant genes and clinical indexes to identify high-risk patients with stage III/IV colorectal cancer.

Authors:  Kai Liu; Cui Wang; Jiefu Wang; Yang Zhan; Xin Yue; Dalu Kong
Journal:  J Gastrointest Oncol       Date:  2020-12

2.  Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis.

Authors:  Jiefeng Zhao; Jinfeng Zhu; Rui Sun; Chao Huang; Rongfa Yuan; Zhengming Zhu
Journal:  BMC Cancer       Date:  2021-05-06       Impact factor: 4.430

3.  Establishment of an immune-related gene pair model to predict colon adenocarcinoma prognosis.

Authors:  Jihang Luo; Puyu Liu; Leibo Wang; Yi Huang; Yuanyan Wang; Wenjing Geng; Duo Chen; Yuju Bai; Ze Yang
Journal:  BMC Cancer       Date:  2020-11-09       Impact factor: 4.430

4.  Analysis of multi-omics differences in left-side and right-side colon cancer.

Authors:  Yanyi Huang; Jinzhong Duanmu; Yushu Liu; Mengyun Yan; Taiyuan Li; Qunguang Jiang
Journal:  PeerJ       Date:  2021-05-12       Impact factor: 2.984

5.  Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status.

Authors:  Bassem Refaat; Jamal Zekri; Akhmed Aslam; Jawwad Ahmad; Mohammed A Baghdadi; Abdelrazak Meliti; Shakir Idris; Sufian Sultan; Hosam Alardati; Haitham Akram Saimeh; Aiman Alsaegh; Mai Alhadrami; Tahira Hamid; Mohammed E Naeem; Shereef Ahmed Elsamany
Journal:  Pathol Oncol Res       Date:  2021-11-15       Impact factor: 3.201

6.  Analysis of prognosis, genome, microbiome, and microbial metabolome in different sites of colorectal cancer.

Authors:  Yang Xi; Pan Yuefen; Wu Wei; Qi Quan; Zhuang Jing; Xu Jiamin; Han Shuwen
Journal:  J Transl Med       Date:  2019-10-29       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.